IntegraGen Reports €5.6m in Revenues for H1 2023 Representing 13% Decrease Compared to H1 2022 and a Cash Position of €4.3m
- Decline in microbiology sequencing platform activity after a
strong contribution in the first half of 2022 in connection with
the Covid-19 pandemic. Adjusted for this base effect, growth was 6%
over the period.
- Slight decrease in revenues recognized by the Evry R&D
IntegraGen (FR0010908723 – ALINT), an OncoDNA Group
company specializing in the decryption of the human genome which
performs interpretable genomic analyzes for academic and private
laboratories and develops diagnostic tools for oncology, announced
today its unaudited revenue figures for the first half of 2023.
The first half of 2023 unaudited revenue amount to €5,628k,
representing a decrease of 13% compared to the first half of 2022.
This decrease mainly reflects unfavorable base effect with H1 2022,
which had benefited from strong activity on the microbiology
sequencing platform operated on behalf of a third parties in
response to the Covid-19 pandemic. Excluding revenues from this
platform, revenues would have risen by 6% over the period. This
amount does not include the recharge of personnel costs to the
Sequencing activities for R&D are in line with those
recorded in H1 2022. Several major projects were carried out on the
company's Évry platform. Clinical research activities in oncology
continue to grow, as do other outsourced activities.
As of the end of June 2023, the company’s cash position was
€4,285k, which represents a slight decrease of €0.2m compared with
the cash position of December 31, 2022. The position includes a
state guaranteed loan (Prêt Garanti par l’État, PGE) for an
outstanding amount of €1,317 k obtained in 2020 in response to the
pandemic. The change over the past six months is essentially due to
the reimbursement of this loan.
With a stable order book at the end of June, growth prospects
remain established on the basis of current sales dynamics,
multi-year contracts in place and revenue synergies activated
within the OncoDNA Group.
Bernard Courtieu, IntegraGen CEO, said “In this first
year without the benefit of the exceptional requirements linked to
COVID-19, the 3% increase in IntegraGen's business activity,
adjusted for this unfavorable base effect, demonstrates the
robustness of our business model, as well as the strategic
relevance of developing our portfolio of oncology sequencing
offerings. This is what we are doing with conviction in 2023
through the deployment of solutions to support the development of
oncology molecules based on the targeting and monitoring of
patients in clinical trials. This innovative, high-potential
initiative will enable us to exploit new sources of growth in
synergy with the OncoDNA Group since the merger in 2021.”.
The financial results for H1 of 2023 will be published on
October 20th, 2023.
IntegraGen is an OncoDNA Group company specializing in the
genomics of cancer and rare genetic diseases. Backed by highly
competent and qualified teams, IntegraGen is a leading player in
DNA sequencing services and genomic data interpretation software.
The company runs one of the largest NGS labs in France and operates
for research institutes of excellence. As part of OncoDNA Group,
IntegraGen leverages the power of next generation sequencing with
the mission of delivering the promise of precision medicine to
patients. IntegraGen has about 55 employees and generated €12,6
millions of turnover in 2022. Based in France, IntegraGen is part
of the Belgian OncoDNA Group present in Spain, UK, Germany and
works with an international network of 35 distributors. The Group
also provides biomarker testing and clinical interpretation tools
to guide treatment and monitoring of latestage solid tumors and
accelerate the development of new cancer drugs.
IntegraGen is listed on Euronext Growth in Paris (ISIN:
FR0010908723 – Mnemo: ALINT – Eligible PEA- PME).
For further information, visit www.integragen.com and connect
with us on LinkedIn or Twitter.
version on businesswire.com: https://www.businesswire.com/news/home/20230712699837/en/
INTEGRAGEN Bernard COURTIEU CEO Pierre FLAMANT CFO
email@example.com Tél. : +33 (0)1 60 91 09 00 NEWCAP
Investor Relation Louis-Victor DELOUVRIER firstname.lastname@example.org
Tél. : +33 (0)1 44 71 98 53
Graphique Historique de l'Action
De Jan 2024 à Fév 2024
Graphique Historique de l'Action
De Fév 2023 à Fév 2024